Displaying drugs 15201 - 15225 of 15304 in total
Bioymifi
Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic. Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.[A257048,A257053]
Investigational
CHGN111
CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase. Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative stress. It...
Investigational
1,1,1-TRIFLUORO-3-(OCTYLTHIO)ACETONE
Experimental
8-azaxanthine
Experimental
3,5-Diaminophthalhydrazide
Experimental
Nitrosoethane
Experimental
Amitifadine
Investigational
Napabucasin
Napabucasin has been investigated for the treatment of Colorectal Carcinoma.
Investigational
ING-1
ING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most adenocarcinomas. It is an attractive target for immunotherapy.
Investigational
R450
R450 is an alpha 1 antagonist that acts to tighten the muscle tone in the bladder. It is being considered for treatment of stress-related urinary incontinence. Phase IIa data for the drug show it reduced the number of incontinent episodes compared to placebo with minimal cardiovascular effects.
Investigational
R1295
R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis. Integrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid arthritis.
Investigational
Pridopidine
Pridopidine has been used in trials studying the treatment of Huntington's Disease.
Investigational
Oxomemazine
Experimental
MBT-0312
MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
Investigational
9-Deazahypoxanthine
Experimental
ISIS 113715
ISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes. In early trials, ISIS 113715 induced statistically significant improvements in multiple measures of glucose control along with statistically significant
reductions in LDL-cholesterol.
Investigational
EVT 201
EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.
Investigational
2-Methyl-3-(2-Aminothiazolo)Propanal
Experimental
Methyl isocyanate
Methyl isocyanate has been investigated for the treatment of Nosocomial Pneumonia.
Investigational
ICA-105665
ICA-105665 is a novel small molecule compound for the treatment of epilepsy. It is a novel opener of the KCNQ ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy. In addition, ICA-105665 has also demonstrated activity in certain models of neuropathic pain.
Investigational
Displaying drugs 15201 - 15225 of 15304 in total